Kadcyla (trastuzumab emtansine)

Kadcyla is an Antibody Drug Conjugate (ADC), which combines the HER2-targeting properties of Herceptin (trastuzumab) and the cytotoxic chemotherapy agent DM1. In Kadcyla, trastuzumab and DM1 are joined together using a ‘stable linker’ to deliver DM1 directly to HER2-positive cancer cells.1

Kadcyla is approved as a single agent in the US, EU and many other countries for the treatment of people with HER2-positive advanced breast cancer who previously received Herceptin and taxane chemotherapy, separately or in combination.1

In Bangladesh Kadcyla is approved for the following indications.2

Kadcyla, as a single agent, is indicated for the treatment of patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane.

Kadcyla, as a single agent, is indicated for the adjuvant treatment adult of patients with HER2-positive early breast cancer who have residual disease, breast and/or lymph nodes after pre-operative systemic treatment that included HER2 targeted therapy.

For more disease and medicine related queries you may discuss with your physician.

In Bangladesh Kadcyla is available as

Vials 100 mg

Vials 160 mg

Are a woman who could become pregnant, or may be pregnant

• If a patient becomes pregnant while receiving Kadcyla, or within 7 months following the last dose of Kadcyla, please immediately report pregnancy to the local RocheAdverse Event Line atand/ or

• Additional information will be requested during a Kadcyla-exposed pregnancy and the first year of the infant’s life. This will enable Roche to better understand the safety of Kadcyla and to provide appropriate information to health authorities, healthcare providers, and patients

• For additional information, please refer to